pharmaceutical investing Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial
pharmaceutical investing Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs
pharmaceutical investing Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis
pharmaceutical investing Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
Precious Metals & Critical Minerals Virtual Investor Conference Agenda Announced for July 22nd & 23rd
Metalsource Mining Identifies High Priority Drill Targets Across 2.4 Kilometres to Drive the Next Phase of Exploration at Silver Hill
Skyharbour Signs Letter of Intent with Purecore to Option its Yurchison Uranium Property in the Athabasca Basin
Purecore Signs Letter of Intent with Skyharbour to Option the Yurchison Uranium Property in Athabasca Basin
Finlay Minerals announces the commencement of its 2026 Exploration Programs on its PIL & ATTY Properties
